A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Pharma-Bio Serv, Inc.
PBSV
$15M
Mkt Cap
$0.58
+0.00%
Pharma-Bio Serv, Inc. (PBSV) has a 5-year average return on invested capital (ROIC) of 5.6%. This is below average and may indicate limited pricing power.
Pharma-Bio Serv, Inc. (PBSV) has a market capitalization of $13M. It is classified as a small-cap stock.
Yes, Pharma-Bio Serv, Inc. (PBSV) pays a dividend with a trailing twelve-month yield of 11.81%. The company also returns capital through share buybacks, with a buyback yield of 0.25%.
Pharma-Bio Serv, Inc. (PBSV) operates in the Services-Management Consulting Services industry, within the Industrials sector.
Pharma-Bio Serv, Inc. (PBSV) reported annual revenue of $9 million in its most recent fiscal year, based on SEC EDGAR filings.
Pharma-Bio Serv, Inc. (PBSV) has a net profit margin of -1.1%. The company is currently unprofitable.
Pharma-Bio Serv, Inc. (PBSV) generated $-222 thousand in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Pharma-Bio Serv, Inc. (“Pharma-Bio” or the “Company”) is a Delaware corporation organized on January 14, 2004. The Company operates in Puerto Rico, the United States, Europe and Brazil under the name of Pharma-Bio Serv, and is engaged in providing technical compliance consulting services to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies. References to “we,” “us,” “our” and similar words in this Annual Report on Form 10-K refer to Pharma-Bio Serv, Inc. and its subsidiaries. Our website is www.pbsvinc.com. Information on our website or any other website is not part of this Annual Report on Form 10-K. We are a regulatory affairs, quality, compliance and technology transfer services consulting firm with headquarters in Puerto Rico, servicing the Puerto Rico, United States and European markets, and to a lesser extent the Brazilian market.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 8.8M | 9.0M | 9.5M | 17M | 19M | 20M |
| Net Income | -76K | -100K | -778K | 1.3M | 1.0M | -2.1M |
| EPS | $-0.00 | $-0.00 | $-0.03 | $0.06 | $0.04 | $-0.09 |
| Free Cash Flow | -185K | -222K | -726K | 1.9M | 573K | 794K |
| ROIC | -3.7% | -0.8% | -5.2% | 5.4% | 38.5% | -10.0% |
| Gross Margin | 32.5% | 32.3% | 26.5% | 29.8% | 25.2% | 26.6% |
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.23 | 0.03 | 0.03 |
| Dividends/Share | $0.00 | $0.07 | $0.08 | $0.07 | $0.15 | $0.08 |
| Operating Income | -640K | -638K | -1.3M | 1.1M | 1.2M | -3.9M |
| Operating Margin | -7.3% | -7.1% | -13.5% | 6.6% | 6.1% | -19.2% |
| ROE | -0.7% | -0.8% | -5.2% | 8.0% | 5.7% | -10.0% |
| Shares Outstanding | 23M | 25M | 23M | 23M | 23M | 23M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 28M | 23M | 20M | 13M | 18M | 20M | 22M | 20M | 19M | 17M | 9.5M | 9.0M | 8.8M |
| Gross Margin | 32.6% | 32.0% | 29.6% | 28.9% | 32.0% | 31.7% | 30.9% | 26.6% | 25.2% | 29.8% | 26.5% | 32.3% | 32.5% |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | 6.1M | 5.7M | 5.9M | 4.7M | 4.6M | 4.5M | 4.4M | 9.2M | 3.7M | 3.9M | 3.8M | 3.5M | 3.5M |
| EBIT | 2.9M | 1.8M | -92K | -778K | -1.3M | 1.7M | 2.2M | -3.9M | 1.2M | 1.1M | -1.3M | -638K | -640K |
| Op. Margin | 10.4% | 7.6% | -0.5% | -5.8% | -7.1% | 8.7% | 10.3% | -19.2% | 6.1% | 6.6% | -13.5% | -7.1% | -7.3% |
| Net Income | 2.4M | 1.6M | -257K | -1.4M | 1.3M | 2.1M | 2.1M | -2.1M | 1.0M | 1.3M | -778K | -100K | -76K |
| Net Margin | 8.8% | 6.9% | -1.3% | -10.6% | 7.2% | 10.7% | 9.5% | -10.4% | 5.2% | 7.7% | -8.2% | -1.1% | -0.9% |
| Non-Recurring | 16K | 0 | 14K | 0 | 2.7M | 0 | -13K | 7K | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | 11.7% | 7.4% | -1.2% | -6.6% | 5.8% | 30.7% | 23.8% | -10.0% | 38.5% | 5.4% | -5.2% | -0.8% | -3.7% |
| ROE | 12.5% | 7.7% | -1.2% | -6.6% | 6.2% | 10.2% | 9.5% | -10.0% | 5.7% | 8.0% | -5.2% | -0.8% | -0.7% |
| ROA | 10.8% | 6.9% | -1.1% | -6.1% | 5.4% | 8.0% | 7.3% | -7.8% | 4.5% | 6.5% | -4.3% | -0.7% | -0.6% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 3.3M | 373K | 710K | -923K | 3.7M | -2.2M | 1.5M | 805K | 592K | 1.9M | -567K | -215K | -176K |
| Free Cash Flow | 3.1M | 30K | -1.1M | -980K | 3.6M | -2.3M | 1.5M | 794K | 573K | 1.9M | -726K | -222K | -185K |
| Owner Earnings | 2.9M | -72K | 308K | -1.1M | 3.6M | -2.3M | 1.4M | 676K | 470K | 1.8M | -638K | -310K | -548K |
| CapEx | 208K | 342K | 1.8M | 57K | 122K | 57K | 56K | 11K | 19K | 7K | 160K | 7K | 9K |
| Maint. CapEx | 377K | 357K | 313K | 108K | 75K | 99K | 86K | 73K | 51K | 48K | 23K | 60K | 340K |
| Growth CapEx | 0 | 0 | 1.5M | 0 | 47K | 0 | 0 | 0 | 0 | 0 | 136K | 0 | 0 |
| D&A | 377K | 357K | 313K | 108K | 75K | 99K | 86K | 73K | 51K | 48K | 23K | 60K | 340K |
| CapEx/OCF | 6.2% | 91.9% | 254.9% | N/A | 3.3% | N/A | 3.7% | 1.3% | 3.3% | 0.4% | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 1.7M | 1.7M | 3.4M | 1.7M | 1.7M | 1.7M | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | 15.3% | 10.8% | 26.5% | 11.9% | 13.0% | 15.0% | N/A |
| Share Buybacks | 18K | 169K | 46K | 15K | 57K | 88K | 2K | 26K | 82K | 34K | 11K | 31K | 33K |
| Buyback Yield | 0.1% | 1.6% | 0.5% | 0.3% | 0.5% | 0.9% | 0.0% | 0.2% | 0.6% | 0.2% | 0.1% | 0.2% | 0.2% |
| Stock-Based Comp | 94K | 87K | 89K | 64K | 52K | 34K | 43K | 56K | 72K | 45K | 48K | 35K | 33K |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | N/A | N/A | N/A | N/A | -13M | -15M | -14M | -17M | -14M | N/A | -13M | -11M | -11M |
| Cash & Equiv. | 15M | 15M | 14M | 12M | 16M | 15M | 17M | 17M | 14M | 10M | 6.8M | 3.4M | 11M |
| Long-Term Debt | N/A | N/A | N/A | N/A | 3.0M | 67K | 55K | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.13 | 0.10 | 0.10 | 0.08 | 0.15 | 0.00 | 0.12 | 0.03 | 0.03 | 0.23 | 0.01 | 0.00 | 0.00 |
| Interest Coverage | 398.6 | 242.6 | -26.8 | -264.0 | -842.3 | 417.7 | 575.2 | -2744.8 | N/A | N/A | N/A | N/A | N/A |
| Equity | 21M | 22M | 22M | 21M | 20M | 21M | 23M | 19M | 17M | 16M | 14M | 12M | 10M |
| Total Assets | 23M | 24M | 24M | 22M | 25M | 27M | 30M | 24M | 21M | 20M | 16M | 14M | 14M |
| Total Liabilities | 2.7M | 2.2M | 2.2M | 1.6M | 5.1M | 6.0M | 7.2M | 5.0M | 4.1M | 3.8M | 2.6M | 1.7M | 3.3M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | 20M | 21M | 21M | 20M | 19M | 19M | 22M | 18M | 15M | 15M | 12M | 11M | 8.8M |
| Working Capital | 20M | 21M | 19M | 20M | 21M | 22M | 25M | 20M | 18M | 17M | 14M | 12M | 10M |
| Current Assets | 22M | 23M | 22M | 22M | 23M | 26M | 29M | 23M | 20M | 19M | 16M | 13M | 13M |
| Current Liabilities | 2.6M | 2.1M | 2.2M | 1.5M | 2.6M | 3.7M | 3.8M | 2.7M | 2.1M | 2.2M | 1.9M | 1.7M | 3.3M |
| Per Share Data | |||||||||||||
| EPS | 0.10 | 0.07 | -0.01 | -0.06 | 0.06 | 0.09 | 0.09 | -0.09 | 0.04 | 0.06 | -0.03 | -0.00 | -0.00 |
| Owner EPS | 0.12 | -0.00 | 0.01 | -0.05 | 0.16 | -0.10 | 0.06 | 0.03 | 0.02 | 0.08 | -0.03 | -0.01 | -0.02 |
| Book Value | 0.87 | 0.93 | 0.94 | 0.89 | 0.88 | 0.89 | 0.99 | 0.82 | 0.72 | 0.70 | 0.60 | 0.47 | 0.45 |
| Cash Flow/Share | 0.14 | 0.02 | 0.03 | -0.04 | 0.16 | -0.10 | 0.07 | 0.04 | 0.03 | 0.08 | -0.02 | -0.01 | 0.01 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.08 | 0.07 | 0.08 | 0.15 | 0.07 | 0.08 | 0.07 | 0.00 |
| Shares Out. | 23.7M | 23.5M | 23.3M | 23.2M | 23.1M | 23.2M | 23.0M | 23.0M | 22.9M | 23.0M | 22.9M | 25.1M | 22.9M |
| Valuation | |||||||||||||
| P/E Ratio | 5.1 | 6.3 | N/A | N/A | N/A | 4.8 | 7.3 | N/A | 13.0 | 10.6 | N/A | N/A | -174.6 |
| P/FCF | 4.0 | 339.5 | N/A | N/A | 3.4 | N/A | 10.3 | 16.7 | 22.8 | 7.4 | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 0.6 | 0.5 | 0.5 | 0.2 | 0.6 | 0.5 | 0.7 | 0.7 | 0.8 | N/A | 0.7 | 1.2 | 1.3 |
| Price/Sales | 0.6 | 0.5 | 0.5 | 0.5 | 0.4 | 0.6 | 0.5 | 0.8 | 0.7 | 0.9 | 1.4 | 1.3 | 1.5 |
| FCF Yield | 25.3% | 0.3% | -11.0% | -20.9% | 29.2% | -22.8% | 9.7% | 6.0% | 4.4% | 13.6% | -7.2% | -1.6% | -1.4% |
| Market Cap | 12M | 10M | 10.0M | 4.7M | 12M | 9.9M | 15M | 13M | 13M | 14M | 10M | 14M | 13M |
| Avg. Price | 0.74 | 0.51 | 0.39 | 0.32 | 0.28 | 0.49 | 0.49 | 0.70 | 0.57 | 0.63 | 0.58 | 0.46 | 0.58 |
| Year-End Price | 0.52 | 0.44 | 0.43 | 0.20 | 0.53 | 0.43 | 0.65 | 0.58 | 0.57 | 0.60 | 0.44 | 0.57 | 0.58 |
Pharma-Bio Serv, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 5.6% with a gross margin of 28.1%. Total shareholder yield (dividends + buybacks) is 12.1%. At current prices, the estimated annualized return to fair value is +6.5%.
Pharma-Bio Serv, Inc. (PBSV) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Pharma-Bio Serv, Inc. (PBSV) reported earnings per share (EPS) of $-0.00 in its most recent fiscal year.
Pharma-Bio Serv, Inc. (PBSV) has a return on equity (ROE) of -0.8%. A negative ROE may indicate losses or negative equity.
Pharma-Bio Serv, Inc. (PBSV) has a 5-year average gross margin of 28.1%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 16 years of financial data for Pharma-Bio Serv, Inc. (PBSV), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Pharma-Bio Serv, Inc. (PBSV) has a book value per share of $0.47, based on its most recent annual SEC filing.